Learn More
Invitrogen™ NME1 Monoclonal Antibody (13C1)

Description
Positive Control: K562 cell, A549 cell, HepG2 cell, 293 cell, human liver carcinoma tissue, human thyroid tissue, human skin tissue, human breast carcinoma tissue.
Specifications
Specifications
| Antigen | NME1 |
| Applications | Flow Cytometry, Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | 13C1 |
| Concentration | 2 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol, 0.2% BSA and 0.05% sodium azide; pH 7.4 |
| Gene | NME1 |
| Gene Accession No. | P15531 |
| Gene Alias | AL024257; AWD; expressed in non-metastatic cells 1; expressed in non-metastatic cells 1 protein; expressed in non-metastatic cells 1 protein (NM23A) (nucleoside diphosphate kinase); expressed in non-metastatic cells 1, protein; expressed in non-metastatic cells 1, protein (NM23A) (nucleoside diphosphate kinase); GAAD; Granzyme A activated DNase (GAAD); Granzyme A-activated DNase; GZMA activated DNase; included; metastasis inhibition factor NM23; NB; NBR-A; NBR-B; NBS; NDK A; NDK A 1; NDK A 2; NDK NBR-A; NDK NBR-B; NDKA; NDP kinase A; NDP kinase A 1; NDP kinase A 2; NDP kinase beta; NDP kinase NBR-A; NDPKA; NDPK-A; NM23; NM23A; NM23-C1; NM23-H1; NM23H1B; nm23-M1; NME/NM23 nucleoside diphosphate kinase 1; Nme1; NME1-1; NME1-NME2 spliced read-through transcript; non-metastatic cells 1, protein (NM23A) expressed in; nucleoside diphosphate kinase A; nucleoside diphosphate kinase A 1; nucleoside diphosphate kinase A 2; nucleoside diphosphate kinase NBR-B; nucleoside-diphosphate kinase 1; nucleoside-diphosphate kinase NBR-A; nucleotide diphosphate kinase; nucloside diphosphate kinase; tumor metastatic process-associated protein |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.